SCHEMBL11963751

SCHEMBL11963751

O=C(O)c1cccc(Nc2ncncn2)c1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RHOA P61586 1/20 0.67
NPC1 O15118 2/20 0.61
RAB9A P51151 2/20 0.61
ABL1 P00519 1/20 0.56
BCR P11274 1/20 0.56
PRKCA P17252 1/20 0.56
L3MBTL1 Q9Y468 1/20 0.52
AKR1C3 P42330 4/20 0.51
AKR1C2 P52895 4/20 0.51
MEN1 O00255 2/20 0.51
KMT2A Q03164 2/20 0.51
KDM4E B2RXH2 1/20 0.51
TOP2A P11388 1/20 0.51
ALDH1A1 P00352 1/20 0.51
GAA P10253 1/20 0.51
HTT P42858 1/20 0.51
AURKA O14965 4/20 0.51
AKR1B10 O60218 1/20 0.50
AKR1B1 P15121 1/20 0.50
AKR1C4 P17516 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12504952 0.86 ROCK1 (0.55) RHOAABL1BCRAURKA
SCHEMBL14313819 0.83 SCN9A (0.57)
SCHEMBL30633056 0.83 RHOA (0.93) RHOANPC1RAB9AABL1BCR
SCHEMBL22151485 0.83 AKR1C3 (0.44) RHOANPC1RAB9AABL1BCR
SCHEMBL26135613 0.83 RHOA (0.93) RHOANPC1RAB9AABL1BCR
SCHEMBL28386177 0.82 RHOA (0.64) RHOANPC1RAB9AABL1BCR
SCHEMBL11136814 0.81 AURKA (0.58) NPC1RAB9ATOP2AAURKA
SCHEMBL27705134 0.81 RHOA (0.62) RHOANPC1RAB9AABL1BCR
SCHEMBL27040648 0.79 RHOA (0.60) RHOANPC1RAB9AABL1BCR
SCHEMBL21925297 0.77 RHOA (0.77) RHOANPC1RAB9AABL1BCR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2948445-A1 GUANIDINE DERIVATIVES FOR THE TREATMENT OF HEPATITIS C Bristol-Myers Squibb Company (US) 2015-12-02 EP disclosed
WO-2014116768-A1 GUANIDINE DERIVATIVES FOR THE TREATMENT OF HEPATITIS C BRISTOL-MYERS SQUIBB COMPANY (US) 2014-07-31 WO disclosed
EP-2697230-A1 COMPOUNDS FOR THE TREATMENT OF HEPATITIS C Bristol-Myers Squibb Company (US) 2014-02-19 EP disclosed
EP-2566872-A1 COMPOUNDS FOR THE TREATMENT OF HEPATITIS C Bristol-Myers Squibb Company (US) 2013-03-13 EP disclosed
WO-2012141704-A1 COMPOUNDS FOR THE TREATMENT OF HEPATITIS C BRISTOL-MYERS SQUIBB COMPANY (US) 2012-10-18 WO disclosed
EP-2488526-A1 COMPOUNDS FOR THE TREATMENT OF HEPATITIS C Bristol-Myers Squibb Company (US) 2012-08-22 EP disclosed